Scynexis Taps Rare Disease Specialist as R&D Chief
Event summary
- Scynexis appoints Todd Minga, M.D., as Senior Vice President, Research & Development, effective September 14, 2026.
- Dr. Minga brings over 20 years of experience in kidney disease and rare disorders, most recently from Akebia Therapeutics.
- He was granted options to purchase 40,000 shares at $4.60 per share and 5,000 restricted stock units (RSUs).
- Scynexis focuses on rare diseases, with SCY-770 for ADPKD and SCY-247 in antifungal development.
The big picture
Scynexis’ appointment of Dr. Minga underscores its push into rare disease therapeutics, particularly in nephrology. His background in both clinical medicine and drug development aligns with the company’s focus on ADPKD and antifungal innovations. The move comes as biotech firms increasingly target orphan drug designations to secure faster approvals and premium pricing.
What we're watching
- Pipeline Progress
- How Dr. Minga’s leadership will accelerate SCY-770 and SCY-247 development timelines.
- Regulatory Strategy
- Whether his experience will streamline interactions with regulators for rare disease approvals.
- Talent Retention
- The pace at which Scynexis can retain top-tier R&D talent amid competitive biotech hiring.
Related topics